Ascofuranone
Ascofuranone is an orally active inhibitor of Trypanosoma brucei brucei (TAO) with a Ki value of 2.38 nM. Ascofuranone inhibits IGF-1-induced cancer cell migration, invasion, motility and actin cytoskeleton formation, and exerts anti-tumor effects. Ascofuranone can be used in research related to tumor metastasis, African trypanosomiasis, bacterial infections, lung cancer and hepatocellular carcinoma.
For research use only. We do not sell to patients.
- CAS No.: 38462-04-3
- Formula: C23H29ClO5
- Molecular Weight:420.93
-
Storage:Pure form -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
0.9 μM
Compound: 10
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay
|
[PMID: 34781681] |
| C3H 10T1/2 | IC50 |
3.2 μM
Compound: 20
|
Concentration required for inhibition of C3H10T1/2 progenitor cell growth
Concentration required for inhibition of C3H10T1/2 progenitor cell growth
|
[PMID: 12954063] |
| HepG2 | IC50 |
0.9 μM
Compound: 10
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay
|
[PMID: 34781681] |
| MDA-MB-231 | IC50 |
5.2 μM
Compound: 15
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent assay
|
[PMID: 34516133] |
| MDA-MB-468 | IC50 |
7.1 μM
Compound: 15
|
Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent assay
Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent assay
|
[PMID: 34516133] |
In Vitro
Ascofuranone (1-20 μM; 24 h) reduces cell viability in a dose-dependent manner in A549, PC3, and MCF-7 cancer cells, but shows limited cytotoxicity in LL24 normal lung cells at concentrations up to 20 μM[1].
Ascofuranone (10 μM; 24 h) reduces baseline and IGF-1-induced cell invasion in A549, PC3, and MCF-7 cancer cells by approximately 0.5-fold, but does not alter invasion in LL24 normal lung cells, when used at 10 μM for 24 h[1].
Ascofuranone (0.1-10 μM; 1 h pre-incubation followed by 10 min co-incubation with IGF-1) dose-dependently inhibits IGF-1-induced mTOR phosphorylation, and suppresses IGF-1-induced phosphorylation of the downstream mTOR effectors p70S6K and 4EBP1, in A549, PC3, and MCF-7 cancer cells[1].
Ascofuranone (10 μM; 1 h pre-incubation followed by 4 h co-incubation with IGF-1) activates AMPK and ACC phosphorylation in an IGF-1-independent manner in A549 and PC3 cancer cells, when used at 10 μM with a 1 h pre-incubation followed by 4 h co-incubation with IGF-1[1].
Ascofuranone (10 μM; 1 h pre-incubation followed by 10 min co-incubation with IGF-1) inhibits mTORC1 activity by inducing Raptor phosphorylation at Ser792 and modulating TSC2 phosphorylation, in an IGF-1-independent manner in A549 and PC3 cancer cells, when used at 10 μM with a 1 h pre-incubation followed by 10 min co-incubation with IGF-1[1].
Ascofuranone (1-10 μM; 1 h pre-incubation followed by 10 min co-incubation with IGF-1) dose-dependently inhibits IGF-1-induced FAK phosphorylation in A549 and PC3 cancer cells[1].
Ascofuranone (3 μM; 20 h) activates PXR transcriptional activity in U2OS cells with a minimum effective concentration of 3 μM[2].
Ascofuranone (IC50 3.2 μM; 48 h) inhibits U2OS cell proliferation with an IC50 of 3.2 μM[2].
Ascofuranone significantly induces adipocyte differentiation of C3H10T1/2 cells, independent of PPARγ activation[2].
Ascofuranone (50 nM) inhibits the ubiquinol oxidase activity of TAO-expressing E. coli BL21(DE3)pLysS cytoplasmic membranes, reducing activity to 31.6% of the uninhibited control[3].
Ascofuranone (50 nM) inhibits 23% of the succinate-dependent oxygen consumption activity of TAO-expressing E. coli BL21(DE3)pLysS cytoplasmic membranes when used alone, and completely inhibits the cyanide-insensitive portion of this activity when combined with 5 mM K+CN[3].
Ascofuranone (4-32 μg/mL) exhibits potent antimicrobial activity against select Gram-positive bacteria, including S. aureus, methicillin-resistant S. aureus, S. epidermidis, and B. subtilis, with MIC values ranging from 4 to 32 μg/mL, and against C. albicans with an MIC of 32 μg/mL, but is inactive against vancomycin-resistant E. faecalis (MIC >128 μg/mL)[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:LL24 normal lung cells, A549 lung cancer cells, PC3 prostate cancer cells, MCF-7 breast cancer cells
-
Concentration:1-20 μM
-
Incubation Time:24 h
-
Result:Did not decrease cell viability at doses lower than 5 μM, and resulted in approximately 90% cell viability at 20 μM in LL24 normal lung cells. Significantly decreased cell viability at 5 μM.
-
Cell Line:LL24 normal lung cells, A549 lung cancer cells, PC3 prostate cancer cells, MCF-7 breast cancer cells
-
Concentration:10 μM (co-incubated with IGF-1)
-
Incubation Time:24 h (co-incubated with IGF-1)
-
Result:Did not significantly affect cell invasion in LL24 cells. Inhibited cell invasion by approximately 0.5-fold alone, and also significantly inhibited IGF-1-induced cell invasion in A549, PC3, and MCF-7 cancer cells.
-
Cell Line:LL24 normal lung cells, A549 lung cancer cells, PC3 prostate cancer cells, MCF-7 breast cancer cells
-
Concentration:10 μM (pre-incubated for 1 h, followed by 1 h co-incubation with IGF-1)
-
Incubation Time:1 h pre-incubation, followed by 1 h co-incubation with IGF-1
-
Result:Did not alter F-actin distribution in LL24 cells. Did not change F-actin distribution alone, but prevented IGF-1-stimulated F-actin cytoskeleton organization at the leading edges of cells (lamellipodia and filopodia) in A549, PC3, and MCF-7 cancer cells.
-
Cell Line:A549 lung cancer cells, PC3 prostate cancer cells, MCF-7 breast cancer cells
-
Concentration:0.1-10 μM (pre-incubated for 1 h, followed by 10 min co-incubation with IGF-1; mTOR analysis); 10 μM (pre-incubated for 1 h, followed by 10 min co-incubation with IGF-1; p70S6K and 4EBP1 analysis)
-
Incubation Time:1 h pre-incubation, followed by 10 min co-incubation with IGF-1
-
Result:Significantly decreased IGF-1-induced mTOR phosphorylation in a dose-dependent manner across all three cancer cell lines. Suppressed IGF-1-induced phosphorylation of p70S6K and 4EBP1, downstream effectors of mTOR, in all three cell lines.
-
Cell Line:A549 lung cancer cells, PC3 prostate cancer cells
-
Concentration:10 μM (pre-incubated for 1 h, followed by 4 h co-incubation with IGF-1)
-
Incubation Time:1 h pre-incubation, followed by 4 h co-incubation with IGF-1
-
Result:Increased phosphorylation of AMPK and its downstream target ACC, irrespective of the presence of IGF-1. Resulted in phosphorylation of AMPK and ACC similar to that observed with ascofuranone alone in the presence of IGF-1.
-
Cell Line:A549 lung cancer cells, PC3 prostate cancer cells
-
Concentration:10 μM (pre-incubated for 1 h, followed by 10 min co-incubation with IGF-1)
-
Incubation Time:1 h pre-incubation, followed by 10 min co-incubation with IGF-1
-
Result:Decreased IGF-1-induced Akt phosphorylation in A549 and PC3 cells.
Significantly increased phosphorylation of Raptor at Ser792, a residue that inhibits mTORC1, in an IGF-1-independent manner. Suppressed IGF-1-induced TSC2 phosphorylation at Thr1462, and stimulated TSC2 phosphorylation at Ser1387.
-
Cell Line:A549 lung cancer cells, PC3 prostate cancer cells
-
Concentration:10 μM (co-incubated with IGF-1)
-
Incubation Time:12 h (co-incubated with IGF-1)
-
Result:Decreased IGF-1-stimulated binding of mTOR to Raptor (mTORC1 complex assembly), but did not alter assembly of the mTOR-Rictor (mTORC2) complex.
In Vivo
Ascofuranone (50 mg/kg; i.p.; once every two days; 6 weeks) administered significantly reduces A549 lung metastasis by approximately 80% relative to vehicle control, associated with inhibition of FAK and mTORC1 pathway activity in lung tissues[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (male, 6 weeks old, subcutaneous xenograft model via A549 cell inoculation)[1]
-
Dosage:50 mg/kg
-
Administration:i.p.; once every two days; 28 days
-
Result:Reduced average tumor weight to 0.386 g, compared to 1.33 g in vehicle-treated controls, representing a 71% reduction.
-
Animal Model:BALB/c nude (male, 6 weeks old, metastatic model via tail vein injection of A549 cells)[1]
-
Dosage:50 mg/kg
-
Administration:i.p.; once every two days; 6 weeks
-
Result:Reduced the number of metastatic lung nodules.
Decreased size and density of tumor cells in lung tissues via HE staining.
Suppressed Ki67 expression and significantly decreased phosphorylated mTOR levels in lung tissues via immunohistochemistry.
Confirmed suppressed phosphorylation of FAK and mTOR, and increased phosphorylation of Raptor in lung tissues via Western blot analysis, relative to vehicle control.
Chemical Information
-
CAS No. 38462-04-3
-
Appearance Oil
-
Molecular Weight 420.93
-
Formula C23H29ClO5
-
Color Colorless to light pink
-
SMILES
C/C([C@@H]1CC(C(C)(O1)C)=O)=C\CC/C(C)=C/CC2=C(C(C=O)=C(C(Cl)=C2O)C)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Pure form -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Protocols
-
Scratch/Wound-Healing Migration Assay
The scratch/wound-healing migration assay measures collective migration of adherent cells into an experimentally created cell-free gap in a confluent monolayer. The readout is generated by imaging the gap immediately after scratching and at later time points, then quantifying reduction in wound area, wound width, or percentage closure as cells move into the denuded region. Gap closure reflects cell migration but may also include cell proliferation, so interpretation should distinguish migration-focused conditions from proliferation-driven closure when possible, such as by using short assay windows, serum-controlled conditions, cell counting, or proliferation controls reported in published protocols.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Neural Crest/Neuronal Cell Migration Explant Assay
Neural crest (NC) and neuronal cell migration explant assays are in vitro systems in which neural tube-derived tissues are cultured to allow premigratory or newly emigrated neural crest cells to undergo epithelial-to-mesenchymal transition (EMT), migrate away from the explant, and form a measurable radial outgrowth that reflects migratory capacity and environmental responsiveness. These assays typically quantify migration by measuring the expansion of cell outgrowth from neural tube or neural plate border explants over time, often comparing early and later timepoints to derive a migration index such as a radius ratio, which reflects net cell dispersal from the explant core. Neural tube explant cultures preserve key aspects of neural crest behavior, including EMT, migration, and early differentiation, making them suitable for assessing intrinsic migratory ability and extrinsic cue dependence. However, studies emphasize that migratory outgrowth from neural tube explants may include non-n
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Phalloidin F-actin cytoskeleton staining
Phalloidin F-actin staining detects polymerized filamentous actin in fixed and permeabilized specimens by using fluorescent phalloidin or phalloidin-derived phallotoxins that bind actin filaments and generate a fluorescence microscopy readout corresponding to F-actin organization, including stress fibers, cortical actin, filament bundles, and tissue-specific actin networks. Phalloidin stabilizes F-actin by reducing actin subunit dissociation from filament ends, and fluorescent phallotoxins were established as tools for visualizing actin-containing structures in eukaryotic cells.
-
Chemotaxis Gradient Chamber Assay 1
The chemotaxis gradient chamber assay is based on the principle of observing directional cell migration in response to a stable, linear or quasi-linear concentration gradient of a chemoattractant formed between two fluid reservoirs separated by a narrow observation chamber. Cells placed within the chamber respond to the gradient by polarized movement toward higher chemoattractant concentrations, allowing quantification of chemotactic behavior in real time under microscopy. The classic Zigmond chamber design enables simultaneous visualization of gradient formation and individual cell trajectories, making it suitable for studying leukocyte chemotaxis and other motile cell types in vitro.
-
Under-Agarose Cell Migration Assay
The under-agarose cell migration assay is a classical in vitro chemotaxis method designed to evaluate directed cell movement through a semi-solid agarose matrix toward soluble chemoattractant gradients, enabling visualization and quantification of leukocyte or motile cell migration in a confined 2D-like environment. In this system, cells and chemoattractants are placed in separate wells cut into an agarose gel, allowing diffusion-driven gradient formation that guides directional migration, which is typically assessed by measuring migration distance, cell morphology changes, and accumulation toward the chemoattractant source. This assay has been widely used to study neutrophil and leukocyte chemotaxis as a simple alternative to filter-based migration systems and allows direct microscopic observation of migrating cells under near-physiological confinement conditions.
-
Transwell/Boyden Chamber Migration Assay
The Transwell/Boyden chamber migration assay measures cell movement through a porous membrane separating an upper and lower chamber, usually after a chemoattractant gradient is established by placing cells in the upper chamber and chemoattractant-containing medium in the lower chamber. The readout is generated by quantifying cells that traverse the membrane and appear on the lower membrane surface or in the lower chamber, depending on whether the cell type is adherent or non-adherent. This assay reflects chemotactic or haptotactic migration rather than matrix invasion unless an extracellular-matrix barrier is added to the membrane.
-
3D Collagen/Hydrogel Matrix Migration Assay
The 3D collagen/hydrogel matrix migration assay is based on embedding cells within or on top of a fibrillar collagen type I-rich three-dimensional matrix to model in vivo-like extracellular matrix (ECM) architecture, enabling analysis of cell migration through a physically and biochemically relevant scaffold. In contrast to 2D migration systems, cells in 3D matrices interact with fibrillar collagen networks, requiring coordinated adhesion remodeling and proteolytic or non-proteolytic deformation mechanisms to move through confined spaces, thereby providing a more physiologically relevant readout of invasive and migratory behavior in tissue-like environments. Cell movement in 3D collagen matrices is typically quantified by tracking single-cell trajectories, invasion depth, or matrix penetration over time, reflecting combined effects of cytoskeletal dynamics, cell-ECM adhesion turnover, and ECM remodeling. These systems are widely used to study tumor cell invasion and stromal cell motili
-
Cell invasion
Cell invasion is the ability of cells to migrate from one area to another via the extracellular matrix. Cell invasion is the response of normal and cancer cells to chemical and mechanical stimuli. Before migrating to a new region, the extracellular matrix is degraded by proteases within the cell. Cell invasion often occurs during wound repair, vascularization and inflammation, abnormal tissue invasion, and tumor cell metastasis.
-
Cell-Exclusion Zone Migration Assay
The Cell-Exclusion Zone (CEZ) migration assay is an in vitro 2D cell migration method in which a defined cell-free area is created using removable physical barriers such as silicone stoppers, allowing cells to be seeded around the barrier and subsequently migrate into the cleared zone after barrier removal. This approach enables quantification of collective cell migration by monitoring repopulation of the initially cell-free region over time using microscopy-based imaging. Compared with scratch-based wound healing assays, barrier-based exclusion methods are designed to avoid mechanical damage to the extracellular matrix and reduce injury-induced effects on boundary cells, thereby improving interpretability of migration behavior in vitro. The assay readout is typically the progressive reduction in the cell-free area or the number of cells invading the exclusion zone, reflecting coordinated cell motility relevant to physiological processes such as wound healing, epithelial repair, and ca
-
Chemotaxis Gradient Chamber Assay 2
Chemotaxis gradient chamber assays measure directional cell migration in response to a soluble chemical gradient by imaging cells as they move across a defined observation region; the readout is generated from time-lapse cell trajectories, displacement toward the gradient, forward migration index, trajectory plots, rose/polar plots, and statistical tests of non-random directionality. The Dunn chamber is a direct-viewing glass chamber in which cells migrate across a bridge between control and chemoattractant wells, allowing observation of cells in a linear concentration gradient; related direct-viewing formats include the Insall chamber, which supports defined unidirectional gradients and high numerical-aperture microscopy, and the μ-Slide Chemotaxis chamber, which supports long-term live-cell imaging and gradient characterization with fluorescent dye.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Jeong YJ, et al. Ascofuranone suppresses invasion and F-actin cytoskeleton organization in cancer cells by inhibiting the mTOR complex 1 signaling pathway. Cell Oncol (Dordr). 2020;43(5):793-805. [Content Brief]
[2]. Togashi M, et al. Ascochlorin derivatives as ligands for nuclear hormone receptors. J Med Chem. 2003;46(19):4113-4123. [Content Brief]
[3]. Fukai Y, et al. Functional expression of the ascofuranone-sensitive Trypanosoma brucei brucei alternative oxidase in the cytoplasmic membrane of Escherichia coli. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1999;124(2):141-148. [Content Brief]
[4]. Hao X, et al. Acremopeptaibols A-F, 16-Residue Peptaibols from the Sponge-Derived Acremonium sp. IMB18-086 Cultivated with Heat-Killed Pseudomonas aeruginosa. J Nat Prod. 2021 Nov 26;84(11):2990-3000. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)